Carl R. Jones, D.O.
Education

• 1982-1987: B.S. Medical Technology, West Virginia University, Morgantown, W.V.
• 1988-1992: Doctor of Osteopathy, WV School of Osteopathic Medicine, Lewsiburg, W.V.

Post Graduate Training

• 1992-1993: Rotating Internship, St. Francis Central Hospital, Pittsburgh, Pa.
• 1993-1996: Resident Internal Medicine, Allegheny General Hospital, Allegheny University of the Health Sciences, Pittsburgh, Pa.
• 1996-1999: Fellow Gastroenterology-Administrative Fellow, 1998, Allegheny General Hospital, Allegheny University of the Health Sciences, Pittsburgh, Pa.

Professional Employment

• 07/2011-present: Owner, Nacogdoches Gastroenterology, PLLC, Nacogdoches, Texas; attending physician, Nacogdoches Memorial Hospital
• 1999-07/2011: Attending physician, gastroenterology, Weirton Medical Center, Weirton, W.V.
• 2009-present: Speakers Bureau (Lontronex), Prometheus Laboratories
• 2009-present: Speakers Bureau (Apriso, Xifaxan), Salix Pharmaceuticals
• 2010-present: Speakers Bureau (Asacol), Proctor and Gamble Pharmaceuticals
• 1998-1999: AOA, AGA, Member Nutritional Care Committee, Allegheny General Hospital, Pittsburgh, Pa.
  • Speaker Bureau Amgen Pharmaceutical
  • Speaker Bureau Janssen Pharmaceutical
• 1995-1999: Attending physician - emergency department, Mercy Providence Hospital, Pittsburgh, Pa.
• 1994-1996: Attending physician, North Hills Urgency Care, Pittsburgh, Pa.
• 1994-1996: House physician, North Hills Passavant Hospital, Pittsburgh, Pa.
• 1994-1997: House physician - Continuing Care Center, Allegheny General Hospital, Pittsburgh, Pa.

Accreditations

• Diplomat American Board of Internal Medicine, 1996-2006
• Texas Licensure-#P2129
• West Virginia Licensure-#1707
• BCLS Certified
• ACLS Certified

Awards Received/Research

• Amgen Pharmaceuticals, Hepatology Scholar Award 1998-1999
• Levofloxacin for the Prevention of Spontaneous Bacterial Pertonitis: RC #2225, July, 1997, Allegheny General Hospital, Allegheny University of the Health Sciences
• Consensus Interferon in Naive Hepatitis C: RC #2374, January, 1998-1999, Allegheny General Hospital, Allegheny University of the Health Sciences
• Phase 2 Study of Recombinant Platelet Activating Factor Acetylhydrolase (rPAF-AH) for the Prevention of Post ERCP Pancreatitis: Sub investigator, September, 1997-1999 Allegheny General Hospital, Allegheny University of the Health Sciences
• Induction Therapy with Consensus Interferon in naive CHC: RC #2630, February, 1999 to June 1999, Allegheny General Hospital, Allegheny University of the Health Sciences

Lectures and Presentations

• Case presentation Pittsburgh Intracity, April, 1997 Allegheny General Hospital, Allegheny University of the Health Sciences
• Portal Hypertension - Liver Pathology Conference, December, 1996  Allegheny General Hospital, Allegheny University of the Health Sciences
• Pathophysiology of Nausea and Vomiting - GI Pathology Conference, May 2007, Allegheny General Hospital, Allegheny University of the Health Sciences
• Acute Nonviral Hepatitis - Liver Pathology Conference Allegheny General Hospital, Allegheny University of the Health Sciences
• Ileus and Pseudoobstruction:- GI Pathology Conference, May 1997 Allegheny General Hospital, Allegheny University of the Health Sciences
• Normal Liver: - Liver Pathology Conference, August, 1997, Allegheny General Hospital, Allegheny University of the Health Sciences
• Diarrhea- GI Pathology Conference, January, 1998  Allegheny General Hospital, Allegheny University of the Health Sciences
• Hepatcoellelar Carcinoma - Liver Pathology Conference, April 1998, Allegheny General Hospital, Allegheny University of the Health Sciences
• Hepatitis C: Update and Treatment - March 1998, San Francisco, CA. Speakers Program, Amgen, Inc.
• Hepatitis C: NIH Consensus conference statement - March, 1998 Weirton, W.V. Speakers Program, Amgen, Inc.
• Hepatitis C: Update and Treatment - May 1998 Harrisburg, Pa. Speakers Program, Amgen, Inc.
• Hepatitis C: Therapeutic Update - Invited Guest Lecturer, John Hopkins University Hepatology Research Conference, May 1998
• Complication of ERCP - GI Pathology Conference, August 1998 Allegheny General Hospital, Allegheny University of the Health Sciences
• New Therapies in Hepatitis C - Invited Guest Lecturer, Jennet, Pa. September, 1998 Speakers Program Amgen, Inc.
• Emerging Therapies in Hepatitis C - Invited Guest Lecturer, University of Rochester, Rochester, Pa., Sept. 1998
• New Strategies in Treatment of Hepatitis C - Dinner Program, Sheenan Memorial Hospital, Buffalo, N.Y., Sept. 1998
• Treatment Options in Hepatitis C -Invited Guest Lecturer, High Mark Blue Cross/Blue Shield, Pittsburgh, Pa. Oct. 1998
• Drug Therapies for Hepatitis C - Invited Guest Lecturer and Moderator, Pittsburgh, Pa. Oct. 1998, Speakers Program Amgen, Inc.
• Hepatitis C: New Strategies in Treatment - Buffalo, N.Y. Nov. 1998 Speakers Program Amgen, Inc.
• Strategies in Treatment of Hepatitis C - Invited Guest Lecturer, Fort Worth, Texas, Nov. 1998
• High Dose Consensus Interferon in the Treatment of Naive Hepatitis C Patients - A Preliminary Report - Clinical Development Investigators Meeting: Invited Guest Lecturer, Maui, HI, Dec. 1998
• Primary Sclerosin Cholangitis - G.I. Pathology Conference, January 1999, Allegheny General Hospital, Allegheny University of the Health Sciences
• Update on Hepatitis C - Invited Guest Lecturer, Medical Grand Rounds, River Medical Center, Ocean City, N.Y., March 1999
• Acid or Motility? An Overview of G.I. Problems - Pittsburgh, Pa. Janssen Speaker Program, April 1999
• Hepatitis C in the Prison Population - Invited Lecturer, Pennsylvania Department of Corrections - Expert Panel on Management and Treatment Guidelines, Harrisburg, Pa., April 1999